- Home
- Urology
查找地点
有关时间、上门服务和预约Discover how phi can guide better prostate cancer detection and management.
phi is designed to aid in distinguishing prostate cancer from benign prostatic conditions in patients aged 50 years and older with total PSA ≥4.0 to ≤10.0 ng/mL with digital rectal examination findings that are not suspicious for cancer
VistaSeq® Prostate Panel assay is intended for patients with a personal history of prostate cancer or a family history consistent with an inherited cancer syndrome. In addition, the National Comprehensive Cancer Network (NCCN) Guidelines recommend that patients diagnosed with Grade Group (GG) 1-3 prostate cancers and a suspicious family history should undergo germline testing, and those with GG4 and 5 prostate cancers should be tested as well (source Prostate Cancer. NCCN Guidelines for Patients®, Version 2.2021)
NGS-based genomic and immune profiling assay including RNA-seq, TMB, MSI, and PD-L1 IHC. Comprehensive genomic and immune profiling gives a complete picture of a patient's tumor and details specific treatment options in one easy to-interpret report